The first selective EZH2 inhibitor (tazemetostat) was developed, which demonstrated antitumor activity in B-cell non-Hodgkin lymphoma cell lines and was approved for EZH2-mutated follicular lymphoma [114]. The gene discussed is EZH2; the disease is B-cell non-Hodgkin lymphoma.